Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer

Clinical trial NCT02254005 · COMPLETED

Trial details

NCT number: NCT02254005
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2002-10-01
Primary completion: 2004-12-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.